Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT04547088
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Anti-PD-1 targeted immunotherapy
  • Apatinib — DRUG
    A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor

Study Details

The purpose of this study is to explore the efficacy and safety of a combination of Camrelizumab and Apatinib regimen in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.

Key Dates

Start date
Sep 30, 2020
Status verified
Sep 2020
Primary completion
Oct 31, 2022
Completion
Oct 31, 2023

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Apatinib
    Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.

Primary Outcome Measure

Objective response rate [ Time Frame: 2 years ]

Central Contacts

Related Studies